Clinical efficacy of Azithromycin for COVID-19 management: A systematic meta-analysis of meta-analyses.
Ali Danish Khan Yousafzai, Ali Haider Bangash, Saleha Yurf Asghar and 16 others
PMID 36996755WHAT IT FOUND
Azithromycin did not reduce mortality or the need for mechanical ventilation in patients with COVID-19 compared to standard care.
It also did not significantly increase the risk of arrhythmia or heart rhythm prolongation.
Key findings
01Azithromycin did not significantly reduce mortality compared to standard of care.
02Azithromycin did not significantly reduce the requirement for mechanical ventilation.
03Azithromycin did not significantly induce arrhythmia or prolong the QTc interval.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The analysis included only two meta-analyses, which limits the robustness of the pooled estimates. There was very high statistical heterogeneity in the results, meaning the included studies varied widely in their findings. There was a 20% overlap in the primary studies included in the two meta-analyses, which may have biased the results. The search was limited to English-language publications and indexed databases, potentially missing other relevant evidence.
Declared interests
The authors declared no conflicts of interest.
The easy way to misread this
Do not interpret the lack of significant cardiac side effects as proof of safety for all populations. The high heterogeneity and limited number of included meta-analyses mean the safety and efficacy estimates are imprecise, and the primary finding is the absence of benefit rather than the presence of harm.